{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:48:46Z","timestamp":1779328126857,"version":"3.51.4"},"reference-count":68,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Dopamine receptor\ufeff-blocking antipsychotics, first introduced into clinical practice in 1952, were hailed as a panacea in the treatment of a number of psychiatric disorders. However, within 5\u00a0years, this notion was to be shattered by the recognition of both acute and chronic drug-induced movement disorders which can accompany their administration. Tardive syndromes, denoting the delayed onset of movement disorders following administration of dopamine receptor-blocking (and also other) drugs, have diverse manifestations ranging from the classic oro-bucco-lingual dyskinesia, through dystonic craniocervical and trunk posturing, to abnormal breathing patterns. Although tardive syndromes have been an important part of movement disorder clinical practice for over 60\u00a0years, their pathophysiologic basis remains poorly understood and the optimal treatment approach remains unclear. This review summarises the current knowledge relating to these syndromes and provides clinicians with pragmatic, clinically focused guidance to their management.<\/jats:p>","DOI":"10.1136\/practneurol-2020-002566","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T17:20:09Z","timestamp":1591118409000},"page":"368-376","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Tardive syndromes"],"prefix":"10.1136","volume":"20","author":[{"given":"Eoin","family":"Mulroy","sequence":"first","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Balint","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK"},{"name":"Department of Neurology, University Hospital, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailash P","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2025090411093548000_20.5.368.1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"2025090411093548000_20.5.368.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1996.tb09835.x"},{"key":"2025090411093548000_20.5.368.3","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200004000-00011"},{"key":"2025090411093548000_20.5.368.4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11920-011-0202-6","article-title":"Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment","volume":"13","author":"Lerner","year":"2011","journal-title":"Curr Psychiatry Rep"},{"key":"2025090411093548000_20.5.368.5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00702-013-1108-8","article-title":"Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine","volume":"121","author":"Dressler","year":"2014","journal-title":"J Neural Transm"},{"key":"2025090411093548000_20.5.368.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2010.10.002"},{"key":"2025090411093548000_20.5.368.7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.07m03890yel"},{"key":"2025090411093548000_20.5.368.8","doi-asserted-by":"crossref","unstructured":"Leucht S , Kissling W , Davis JM . Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39:1591. doi: 10.1017\/S0033291709005455","DOI":"10.1017\/S0033291709005455"},{"key":"2025090411093548000_20.5.368.9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first\u2010 and second\u2010generation antipsychotics in comparative randomized controlled trials: a meta\u2010analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"2025090411093548000_20.5.368.10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.050088"},{"key":"2025090411093548000_20.5.368.11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2025090411093548000_20.5.368.12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","article-title":"Tardive dyskinesia: epidemiology","volume":"389","author":"D\u2019Abreu","year":"2018","journal-title":"J Neurol Sci"},{"key":"2025090411093548000_20.5.368.13","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.138.4.297"},{"key":"2025090411093548000_20.5.368.14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20823"},{"key":"2025090411093548000_20.5.368.15","doi-asserted-by":"crossref","unstructured":"Morgenstern H . Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry 1993;50:723. doi: 10.1001\/archpsyc.1993.01820210057007","DOI":"10.1001\/archpsyc.1993.01820210057007"},{"key":"2025090411093548000_20.5.368.16","first-page":"387","article-title":"Incidence of tardive dyskinesia: five-year data from a prospective study","volume":"20","author":"Kane","year":"1984","journal-title":"Psychopharmacol Bull"},{"key":"2025090411093548000_20.5.368.17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/18.4.701"},{"key":"2025090411093548000_20.5.368.18","doi-asserted-by":"publisher","DOI":"10.1176\/ps.41.11.1203"},{"key":"2025090411093548000_20.5.368.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000144888.43449.54"},{"key":"2025090411093548000_20.5.368.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212259","article-title":"Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations","volume":"3","author":"Kim","year":"2014","journal-title":"Drugs Context"},{"key":"2025090411093548000_20.5.368.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2009.02.015"},{"key":"2025090411093548000_20.5.368.22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25107"},{"key":"2025090411093548000_20.5.368.23","doi-asserted-by":"crossref","unstructured":"Waln O , Jankovic J . An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3. doi: 10.7916\/D88P5Z71","DOI":"10.5334\/tohm.165"},{"key":"2025090411093548000_20.5.368.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/121.11.2053"},{"key":"2025090411093548000_20.5.368.25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00428036"},{"key":"2025090411093548000_20.5.368.26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3875-11.2011"},{"key":"2025090411093548000_20.5.368.27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00002826-199112000-00009","article-title":"Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia","volume":"14","author":"De Keyser","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"2025090411093548000_20.5.368.28","doi-asserted-by":"crossref","unstructured":"Lee H-J , Kang S-G . Genetics of tardive dyskinesia. Int Rev Neurobiol 2011;231\u201364. doi: 10.1016\/B978-0-12-381328-2.00010-9","DOI":"10.1016\/B978-0-12-381328-2.00010-9"},{"key":"2025090411093548000_20.5.368.29","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2010.103234"},{"key":"2025090411093548000_20.5.368.30","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100613"},{"key":"2025090411093548000_20.5.368.31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/YIC.0b013e32834aa924","article-title":"Tardive tourette-like syndrome","volume":"26","author":"Fountoulakis","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"2025090411093548000_20.5.368.32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870070110","article-title":"Tardive tremor","volume":"7","author":"Stacy","year":"1992","journal-title":"Mov Disord"},{"key":"2025090411093548000_20.5.368.33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNF.0000000000000061","article-title":"Tetrabenazine for tardive tremor in elderly adults","volume":"38","author":"Kertesz","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"2025090411093548000_20.5.368.34","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870020408"},{"key":"2025090411093548000_20.5.368.35","doi-asserted-by":"crossref","unstructured":"Tominaga H , Fukuzako H , Izumi K , et al. Tardive myoclonus. Lancet 1987;329:322. doi: 10.1016\/S0140-6736(87)92042-3","DOI":"10.1016\/S0140-6736(87)92042-3"},{"key":"2025090411093548000_20.5.368.36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clineuro.2007.09.013","article-title":"Tardive gait","volume":"110","author":"S-H","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"key":"2025090411093548000_20.5.368.37","first-page":"758","article-title":"Toxicity of psychotropic drugs","volume":"57","author":"Hunter","year":"1964","journal-title":"Proc R Soc Med"},{"key":"2025090411093548000_20.5.368.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.6.1826"},{"key":"2025090411093548000_20.5.368.39","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216030-00003"},{"key":"2025090411093548000_20.5.368.40","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1586\/ern.10.58","article-title":"Tardive dyskinesia and withdrawal emergent syndrome in children","volume":"10","author":"Mejia","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"2025090411093548000_20.5.368.41","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080117"},{"key":"2025090411093548000_20.5.368.42","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.39.11.1434","article-title":"Tardive oculogyric crises","volume":"39","author":"FitzGerald","year":"1989","journal-title":"Neurology"},{"key":"2025090411093548000_20.5.368.43","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.44.11.2115","article-title":"Oral and genital tardive pain syndromes","volume":"44","author":"Ford","year":"1994","journal-title":"Neurology"},{"key":"2025090411093548000_20.5.368.44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00002826-199308000-00003","article-title":"Bruxism secondary to chronic antidopaminergic drug exposure","volume":"16","author":"Micheli","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"2025090411093548000_20.5.368.45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005053-198506000-00005","article-title":"Assessment of tardive dyskinesia using the abnormal involuntary movement scale","volume":"173","author":"Lane","year":"1985","journal-title":"J Nerv Ment Dis"},{"key":"2025090411093548000_20.5.368.46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1192\/bjo.2018.55","article-title":"Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis","volume":"4","author":"Balint","year":"2018","journal-title":"BJPsych Open"},{"key":"2025090411093548000_20.5.368.47","doi-asserted-by":"publisher","DOI":"10.1111\/PCN.12270"},{"key":"2025090411093548000_20.5.368.48","first-page":"10","article-title":"Prevalence of spontaneous dyskinesia in schizophrenia","volume":"61","author":"Fenton","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2025090411093548000_20.5.368.49","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.101485"},{"key":"2025090411093548000_20.5.368.50","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e3282f53132"},{"key":"2025090411093548000_20.5.368.51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pnpbp.2005.01.014","article-title":"Clozapine-induced tardive dyskinesia: a case report","volume":"29","author":"Ertugrul","year":"2005","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"2025090411093548000_20.5.368.52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1017\/S0317167100012294","article-title":"Missing Huntington\u2019s disease for tardive dyskinesia: a preventable error","volume":"38","author":"Kumar","year":"2011","journal-title":"Can J Neurol Sci\/J Can Des Sci Neurol"},{"key":"2025090411093548000_20.5.368.53","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx189"},{"key":"2025090411093548000_20.5.368.54","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"2025090411093548000_20.5.368.55","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130121"},{"key":"2025090411093548000_20.5.368.56","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.6.836"},{"key":"2025090411093548000_20.5.368.57","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"2025090411093548000_20.5.368.58","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0269881119862535","article-title":"Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review","volume":"33","author":"Pardis","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2025090411093548000_20.5.368.59","doi-asserted-by":"crossref","unstructured":"Mentzel TQ , van der Snoek R , Lieverse R , et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia. J Clin Psychiatry 2018;79. doi: 10.4088\/JCP.17r11852","DOI":"10.4088\/JCP.17r11852"},{"key":"2025090411093548000_20.5.368.60","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"2025090411093548000_20.5.368.61","first-page":"13","article-title":"Valbenazine and deutetrabenazine for tardive dyskinesia","volume":"15","author":"Touma","year":"2018","journal-title":"Innov Clin Neurosci"},{"key":"2025090411093548000_20.5.368.62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2018.02.013","article-title":"Deep brain stimulation for tardive syndromes: systematic review and meta-analysis","volume":"389","author":"Macerollo","year":"2018","journal-title":"J Neurol Sci"},{"key":"2025090411093548000_20.5.368.63","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/YCT.0b013e31829e0aea","article-title":"Electroconvulsive therapy for a patient with persistent tardive dyskinesia","volume":"29","author":"Peng","year":"2013","journal-title":"J Ect"},{"key":"2025090411093548000_20.5.368.64","doi-asserted-by":"crossref","unstructured":"Amann B , Erfurth A , Grunze H . Treatment of tardive akathisia with clonidine: a case report. Int J Neuropsychopharmacol 1999;2:S1461145799001376. doi: 10.1017\/S1461145799001376","DOI":"10.1017\/S1461145799001376"},{"key":"2025090411093548000_20.5.368.65","doi-asserted-by":"crossref","unstructured":"Emmanuel T . Remission of treatment-resistant depression with tardive akathisia with electroconvulsive therapy. BMJ Case Rep 2019;12:e229714. doi: 10.1136\/bcr-2019-229714","DOI":"10.1136\/bcr-2019-229714"},{"key":"2025090411093548000_20.5.368.66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-2007-1014473","article-title":"Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-a inhibitor","volume":"24","author":"Ebert","year":"1991","journal-title":"Pharmacopsychiatry"},{"key":"2025090411093548000_20.5.368.67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.1993.26","article-title":"Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence","volume":"8","author":"Cavallaro","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"2025090411093548000_20.5.368.68","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2020-002566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:19:48Z","timestamp":1757009988000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2020-002566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,9,21]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/practneurol-2020-002566"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2020-002566","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}